Law360, New York (September 25, 2009, 3:15 PM ET) -- The U.S. Court of Appeals for the Federal Circuit has upheld a lower court's ruling that AstraZeneca Pharmaceuticals LP did not engage in inequitable conduct when seeking a patent for its antipsychotic drug Seroquel, rejecting a challenge by generics makers Sandoz Inc. and Teva Pharmaceutical Industries Ltd.
In a ruling Friday, the appeals court upheld the grant of summary judgment to AstraZeneca by the of the U.S. District Court for the District of New Jersey. The lower court's ruling ended the case because Teva and Sandoz...
Fed. Circ. Upholds AstraZeneca's Seroquel Patent Win
To view the full article, take a free trial now.
